This review is an updated and expanded version of the five prior reviews that were published in this journal in 1997, 2003, 2007, 2012, and 2016. For all approved therapeutic agents, the time frame has been extended to cover the almost 39 years from the first of January 1981 to the 30th of September 2019 for all diseases worldwide and from ∼1946 (earliest so far identified) to the 30th of September 2019 for all approved antitumor drugs worldwide. As in earlier reviews, only the first approval of any drug is counted, irrespective of how many "biosimilars" or added approvals were subsequently identified. As in the 2012 and 2016 reviews, we have continued to utilize our secondary subdivision of a "natural product mimic", or "NM", to join the original primary divisions, and the designation "natural product botanical", or "NB", to cover those botanical "defined mixtures" now recognized as drug entities by the FDA (and similar organizations). From the data presented in this review, the utilization of natural products and/or synthetic variations using their novel structures, in order to discover and develop the final drug entity, is still alive and well. For example, in the area of cancer, over the time frame from 1946 to 1980, of the 75 small molecules, 40, or 53.3%, are N or ND. In the 1981 to date time frame the equivalent figures for the N* compounds of the 185 small molecules are 62, or 33.5%, though to these can be added the 58 S* and S*/NMs, bringing the figure to 64.9%. In other areas, the influence of natural product structures is quite marked with, as expected from prior information, the anti-infective area being dependent on natural products and their structures, though as can be seen in the review there are still disease areas (shown in Table 2) for which there are no drugs derived from natural products. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures and have been used very successfully in the optimization of many recently approved agents, we are still able to identify only two de novo combinatorial compounds (one of which is a little speculative) approved as drugs in this 39-year time frame, though there is also one drug that was developed using the "fragment-binding methodology" and approved in 2012. We have also added a discussion of candidate drug entities currently in clinical trials as "warheads" and some very interesting preliminary reports on sources of novel antibiotics from Nature due to the absolute requirement for new agents to combat plasmid-borne resistance genes now in the general populace. We continue to draw the attention of readers to the recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated"; thus we consider that this area of natural product research should be expanded significantly.

Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019.

Practical methodologies for the synthesis of indoles.

Large-scale applications of transition metal-catalyzed couplings for the synthesis of pharmaceuticals.

140 years ago Adolf von Baeyer proposed the structure of a heteroaromatic compound which revolutionized organic and medical chemistry: indole. After more than a century, indole itself and the complexity of naturally occurring indole derivatives continue to inspire and influence developments in synthetic chemistry. In particular, the ubiquitous presence of indole rings in pharmaceuticals, agrochemicals, and functional materials are testament to the ever increasing interest in the design of mild and efficient synthetic routes to functionalized indole derivatives. This Review emphasizes the achievements in the selective catalytic functionalization of indoles (C-C bond-forming processes) over the last four years.

Catalytic Functionalization of Indoles in a New Dimension

Transition metal-catalyzed cross-coupling reactions of alkyl metals and aryl halides or pseudohalides have emerged as a powerful methodology for the formation of Csp3-Csp2 bonds over the past decades.1 However, significant attention has also been focused on Pdand Ni-catalyzed Csp3-Csp2 bond-forming reactions that involve aryl metals and haloalkyl compounds lacking -hydrogen atoms as cross-coupling partners.2 In contrast, until a few years ago, few examples were reported in the literature concerning transition metalcatalyzed reactions of aryl metals with functionalized alkyl halides including R-halocarbonyl compounds and R-bromosulfones bearing -hydrogen atoms,3 and a single example of Pd-catalyzed cross-coupling reaction of aryl metals and unfunctionalized alkyl halides bearing -hydrogen atoms had been described.4 Only in recent years, successful procedures for the Pd-,5 Ni-,6 Rh-,7 Fe-,8 V-,9 Co-,10 and Cu-catalyzed11 cross-coupling reactions of aryl metals and unfunctionalized alkyl halides bearing -hydrogen atoms have been developed.12 Nevertheless, new, effective, and more environmentallybenignmethodologiesfortheformationof(cyclo)alkyl-aryl bonds, which require a reduced number of synthetic operations, have emerged as valuable alternatives to the conventional cross-coupling reactions. These methodologies (Scheme 1) are based on transition metal-catalyzed simple or 2-fold C-H bond functionalization according to the following approaches: (a) highly regioselective Pd-catalyzed direct arylation reactions of unactivated sp3-hybridized C-H bonds with aryl halides (eq a, Scheme 1);13 (b) Pd-catalyzed direct alkylation reactions of aryl C-H bonds with alkyl metals (eq b, Scheme 1);14 Au-15 or Pdcatalyzed16 direct alkylation reactions of aryl C-H bonds with alkyl halides or pseudohalides (eq c, Scheme 1); (d) Pd-catalyzed arylations of unactivated sp3-hybridized C-H bonds with aryl metals (eq d, Scheme 1);14c (e) Pd-, Ru-, or Cu-catalyzed cross-coupling reactions of sp3-hybridized C-H bonds with arylboronic acids using air as oxidant (eq d, Scheme 1);17 and (f) cross-dehydrogenative coupling of alkyl and aryl C-H bonds (eq e, Scheme 1).18 Finally, great attention, particularly in the past decade, has also been focused on the design, development, and application of transition metal-catalyzed coupling reactions of aryl halides and pseudohalides with a wide variety of substrates containing activated sp3-hybridized C-H bonds (eq f, Scheme 1). A mini-review on this topic was published by Scolastico and Poli in 1999,19 and three excellent reviews that concern the results obtained in this rapidly growing area of extensive research by the groups of Miura, Natsume, Hartwig, and Buchwald up to the end of 2002 were published by Miura,20 Hartwig,21 and Lloyd-Jones22 a few years later. However, the reviews by Miura20 and Hartwig21 were limited in that they fundamentally emphasized the author’s own work and * To whom correspondence should be addressed. E-mail: rossi@dcci.unipi.it. Chem. Rev. 2010, 110, 1082–1146 1082

Transition metal-catalyzed direct arylation of substrates with activated sp3-hybridized C-H bonds and some of their synthetic equivalents with aryl halides and pseudohalides.

La modification apportee dans la synthese de prolines substituees en 3 consiste en l'utilisation de triethyl silane et d'acide trifluoro acetique pour la reduction des pyrrolidine dicarboxylates-2,2 initiaux, et en la protection du N des prolines par le t-butoxycarbonyl; les racemiques obtenus sont ensuite dedoubles

Conformationally constrained amino acids. Synthesis and optical resolution of 3-substituted proline derivatives

Synthesis of an anti-methicillin-resistant Staphylococcus aureus (MRSA) carbapenem via stannatrane-mediated Stille coupling.

A process for the preparation of alkyl esters of N-protected oxo-azacycloalkylcarboxylic acids of Formula III: comprises contacting a ketosulfoxonium ylide of Formula II: with an iridium catalyst to obtain Compound III, wherein PG1 is an amine protective group group; k is 0, 1, or 2; and RU, R1, R2, and R3 are defined herein. An embodiment of the process further com rises contacting a compound of Formula I: with a sulfoxonium halide of formula (RU)3S(O)Z, wherein Z is halide, in the presence of a strong base to obtain Compound II. Additional embodiments add a series of process steps leading to the synthesis of 7-oxo-1,6- diazabicyclo[3.2.1]octanes suitable for use as β-lactamase inhibitors.

Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids

Diastereoselective Friedel−Crafts Alkylation of Indoles with Chiral α-Phenyl Benzylic Cations. Asymmetric Synthesis of Anti-1,1,2-Triarylalkanes

A mild, high-yielding procedure for the preparation of β-ketophosphonates is described. The condensation is general with respect to the ester and phosphonate, and the products are obtained in high yields within minutes at 0 °C. The reaction procedure is operationally simple and amenable to large-scale preparations.

John Y. L. Chung

Papers

Conformationally constrained amino acids. Synthesis and optical resolution of 3-substituted proline derivatives

Synthesis of an anti-methicillin-resistant Staphylococcus aureus (MRSA) carbapenem via stannatrane-mediated Stille coupling.

Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids

Diastereoselective Friedel−Crafts Alkylation of Indoles with Chiral α-Phenyl Benzylic Cations. Asymmetric Synthesis of Anti-1,1,2-Triarylalkanes

A General Procedure for the Preparation of β-Ketophosphonates